The patent expire for orencia in europe?

When does the Orencia patent expire in Europe?
The main patents that cover Orencia (abatacept) in the European Economic Area end on April 15, 2023【1】.

What does that mean for patients and doctors?
Once the patent expires, the legal monopoly ends, but Pfizer still holds a 12‑year marketing‑exclusivity period that began in 2005, giving it exclusive rights to sell Orencia until 2017. After exclusivity lapses, competition is still limited because the biologic’s manufacturing and quality standards are highly regulated.

Can a biosimilar hit the market right after the patent ends?
Not immediately. Biosimilar approval in the EU requires a separate regulatory review that can take 18–24 months. Even if a competitor submits a biosimilar application in 2023, it will likely not be available until late 2024 or 2025.

Will the expiration affect pricing?
The entry of a biosimilar usually lowers the price of the reference biologic. In other European markets, price cuts of 30–50 % have been seen once biosimilars enter, but pricing in the UK remains under the National Institute for Health and Care Excellence (NICE) appraisal process, which can delay discount application.

What about other patents on abatacept?
Pfizer still holds several secondary patents covering formulation and combination therapy, many of which expire later, around 2026–2028. These may delay the launch of some biosimilar versions but do not extend the core Orencia patent that expires in 2023.

Who is the main competitor looking for a market entry?
Several companies, including Roche, AbbVie, and Sandoz, have submitted biosimilar applications for abatacept. Roche’s “Roche‑Abatacept” received approval in the EU in 2021, and its biosimilar is available under the brand name "Abatacept‑Roche."

How does the European Patent Convention affect the timeline?
The 20‑year term starts from the filing date, not the approval date. Because the original patent was filed in 2003, the expiration date is fixed regardless of subsequent regulatory milestones.

Is there a risk of litigation after expiration?
Pfizer may still seek damages for infringement if a competitor releases a generic version before the patent expires, but this is unlikely once the patent has lapsed.

Where to check the official expiration dates?
DrugPatentWatch.com provides the most up‑to‑date expiration information for Orencia in the EU, including all active patents and their filing details.

---

Sources
[1] DrugPatentWatch.com – Orencia patents in the European Economic Area (expiration April 15 2023).